The ubiquitin C-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 1666-1678

  Rolén, Ulrika ^a   Freda, Elio ^a,b   Xie, Jianjun ^a,c   Pfirrmann, Thorsten ^a,d   Frisan, Teresa ^a   Masucci, Maria G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Burkitt's lymphoma; Cell proliferation; Integrin activation; Tumor progression; UCH L1

Indexed keywords

INTEGRIN; PRIMER DNA; UBIQUITIN THIOLESTERASE; UCHL1 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

B-LYMPHOCYTES; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; HUMANS; INTEGRINS; UBIQUITIN THIOLESTERASE; UP-REGULATION;

HUMAN HERPESVIRUS 4;

EID: 72949117023     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00501.x     Document Type: Article

References (50)

1. Ciechanover A, Schwartz AL. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta. 2004 1695 : 3 17.
2. Love KR, Catic A, Schlieker C, et al. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol. 2007 3 : 697 705.
3. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005 123 : 773 786.
4. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 2007 60 : 1397 1402.
5. Masucci MG. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system. Oncogene. 2004 23 : 2107 2115.
6. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987 6 : 2743 2751.
7. Masucci MG, Torsteindottir S, Colombani J, et al. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci USA. 1987 84 : 4567 4571.
8. Frisan T, Zhang QJ, Levitskaya J, et al. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer. 1996 68 : 251 258.
9. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 1995 25 : 1374 1384.
10. Frisan T, Levitsky V, Masucci MG. Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells. Int J Cancer. 2000 88 : 881 888.
11. Gavioli R, Frisan T, Vertuani S, et al. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol. 2001 3 : 283 288.
12. Ovaa H, Kessler BM, Rolen U, et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA. 2004 101 : 2253 2258.
13. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet. 1999 23 : 47 51.
14. Liu Y, Fallon L, Lashuel HA, et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002 111 : 209 218.
15. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000 408 : 101 106.
16. Naze P, Vuillaume I, Destee A, et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett. 2002 328 : 1 4.
17. Yanagisawa TY, Sasahara Y, Fujie H, et al. Detection of the PGP9.5 and tyrosine hydroxylase mRNAs for minimal residual neuroblastoma cells in bone marrow and peripheral blood. Tohoku J Exp Med. 1998 184 : 229 240.
18. Yamazaki T, Hibi K, Takase T, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002 8 : 192 195.
19. Sasaki H, Yukiue H, Moriyama S, et al. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol. 2001 31 : 532 535.
20. Tezel E, Hibi K, Nagasaka T, et al. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 2000 6 : 4764 4767.
21. Aumuller G, Renneberg H, Leonhardt M, et al. Localization of protein gene product 9.5 immunoreactivity in derivatives of the human Wolffian duct and in prostate cancer. Prostate. 1999 38 : 261 267.
22. Schumacher U, Mitchell BS, Kaiserling E. The neuronal marker protein gene product 9.5 (PGP 9.5) is phenotypically expressed in human breast epithelium, in milk, and in benign and malignant breast tumors. DNA Cell Biol. 1994 13 : 839 843. (Pubitemid 24293736)
23. D'Andrea V, Malinovsky L, Berni A, et al. The immunolocalization of PGP 9.5 in normal human kidney and renal cell carcinoma. G Chir. 1997 18 : 521 524.
24. Berendt AR, McDowall A, Craig AG, et al. The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding site. Cell. 1992 68 : 71 81.
25. Fabbri M, Di Meglio S, Gagliani MC, et al. Dynamic partitioning into lipid rafts controls the endo-exocytic cycle of the alphaL/beta2 integrin, LFA-1, during leukocyte chemotaxis. Mol Biol Cell. 2005 16 : 5793 5803.
26. Torsteinsdottir S, Andersson ML, Avila-Carino J, et al. Reversion of tumorigenicity and decreased agarose clonability of an IgH/myc translocation carrying BL line. Int J Cancer. 1989 43 : 273 278.
27. Frazier ME, Ushijima RN, Andrews TK, et al. Comparative studies on cell lines established from normal and radiation-exposed miniature swine. In Vitro. 1979 15 : 1001 1012.
28. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994 78 : 59 66.
29. Mentzer SJ, Gromkowski SH, Krensky AM, et al. LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. J Immunol. 1985 135 : 9 11.
30. van Kooyk Y, van Vliet SJ, Figdor CG. The actin cytoskeleton regulates LFA-1 ligand binding through avidity rather than affinity changes. J Biol Chem. 1999 274 : 26869 26877.
31. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002 298 : 2199 2202.
32. de Bruyn KM, Rangarajan S, Reedquist KA, et al. The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion. J Biol Chem. 2002 277 : 29468 29476.
33. Caballero OL, Resto V, Patturajan M, et al. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene. 2002 21 : 3003 3010.
34. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999 398 : 160 165.
35. Wu K, Chen A, Pan ZQ. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem. 2000 275 : 32317 32324.
36. Bianchi E, Denti S, Granata A, et al. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature. 2000 404 : 617 621.
37. Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 110 : 1631 1638.
38. Hogg N, Henderson R, Leitinger B, et al. Mechanisms contributing to the activity of integrins on leukocytes. Immunol Rev. 2002 186 : 164 171.
39. Cambi A, Joosten B, Koopman M, et al. Organization of the integrin LFA-1 in nanoclusters regulates its activity. Mol Biol Cell. 2006 17 : 4270 4281.
40. Pellinen T, Ivaska J. Integrin traffic. J Cell Sci. 2006 119 : 3723 3731.
41. Kirkin V, Dikic I. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol. 2007 19 : 199 205.
42. Zhang W, Shao Y, Fang D, et al. Negative regulation of T cell antigen receptor-mediated Crk-L-C3G signaling and cell adhesion by Cbl-b. J Biol Chem. 2003 278 : 23978 23983.
43. Choi EY, Orlova VV, Fagerholm SC, et al. Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. Blood. 2008 111 : 3607 3614.
44. Magnifico A, Ettenberg S, Yang C, et al. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem. 2003 278 : 43169 43177.
45. Larsen CN, Price JS, Wilkinson KD. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochem. 1996 35 : 6735 6744.
46. Osaka H, Wang YL, Takada K, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet. 2003 12 : 1945 1958.
47. Das C, Hoang QQ, Kreinbring CA, et al. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci USA. 2006 103 : 4675 4680.
48. Meray RK, Lansbury PT Jr. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J Biol Chem. 2007 282 : 10567 10575.
49. Cole RN, Hart GW. Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem. 2001 79 : 1080 1089.
50. Choi J, Levey AI, Weintraub ST, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. 2004 279 : 13256 13264.